RU2003129057A - Замещенные производные бензофуран-2-карбоксамидов - Google Patents
Замещенные производные бензофуран-2-карбоксамидов Download PDFInfo
- Publication number
- RU2003129057A RU2003129057A RU2003129057/04A RU2003129057A RU2003129057A RU 2003129057 A RU2003129057 A RU 2003129057A RU 2003129057/04 A RU2003129057/04 A RU 2003129057/04A RU 2003129057 A RU2003129057 A RU 2003129057A RU 2003129057 A RU2003129057 A RU 2003129057A
- Authority
- RU
- Russia
- Prior art keywords
- group
- formula
- cyano
- benzofuran
- piperazin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- -1 pyridin-4-ylmethyl Chemical group 0.000 claims 5
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 230000036506 anxiety Effects 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- 206010000599 Acromegaly Diseases 0.000 claims 2
- 201000000736 Amenorrhea Diseases 0.000 claims 2
- 206010001928 Amenorrhoea Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 208000018152 Cerebral disease Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 231100000540 amenorrhea Toxicity 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 230000006651 lactation Effects 0.000 claims 2
- 201000003631 narcolepsy Diseases 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 230000036407 pain Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 230000036299 sexual function Effects 0.000 claims 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010033670 Panic reaction Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000009429 distress Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10112151A DE10112151A1 (de) | 2001-03-14 | 2001-03-14 | Substituierte Benzofuran-2-carbonsäureamide |
| DE10112151.2 | 2001-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2003129057A true RU2003129057A (ru) | 2005-04-10 |
Family
ID=7677358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003129057/04A RU2003129057A (ru) | 2001-03-14 | 2002-02-27 | Замещенные производные бензофуран-2-карбоксамидов |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7244846B2 (enExample) |
| EP (1) | EP1368346A1 (enExample) |
| JP (1) | JP4485743B2 (enExample) |
| KR (1) | KR20030080083A (enExample) |
| CN (1) | CN1244578C (enExample) |
| AR (1) | AR035782A1 (enExample) |
| BR (1) | BR0208040A (enExample) |
| CA (1) | CA2440726C (enExample) |
| CZ (1) | CZ20032712A3 (enExample) |
| DE (1) | DE10112151A1 (enExample) |
| EC (1) | ECSP034798A (enExample) |
| EE (1) | EE200300447A (enExample) |
| HU (1) | HUP0303449A3 (enExample) |
| IL (1) | IL157889A0 (enExample) |
| MX (1) | MXPA03008140A (enExample) |
| PL (1) | PL362844A1 (enExample) |
| RU (1) | RU2003129057A (enExample) |
| SK (1) | SK12492003A3 (enExample) |
| WO (1) | WO2002083666A1 (enExample) |
| ZA (1) | ZA200307966B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2397981C2 (ru) * | 2005-04-26 | 2010-08-27 | Мерк Патент Гмбх | Способ получения 5-(4-[4-(5-циано-3-индолил)бутил]-1-пиперазинил)бензофуран-2-карбоксамида |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10259244A1 (de) * | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | N-(Indolethyl-)cycloamin-Verbindungen |
| DE10305739A1 (de) * | 2003-02-11 | 2004-08-19 | Merck Patent Gmbh | Benzofuranderivate |
| DE10306941A1 (de) | 2003-02-18 | 2004-08-26 | Merck Patent Gmbh | Benzofuranoxyethylamine |
| DE10326939A1 (de) * | 2003-06-16 | 2005-01-05 | Merck Patent Gmbh | Indol-Derivate |
| DE10326940A1 (de) * | 2003-06-16 | 2005-01-05 | Merck Patent Gmbh | Indol-Derivate |
| PE20060373A1 (es) | 2004-06-24 | 2006-04-29 | Smithkline Beecham Corp | Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2 |
| TW200626142A (en) | 2004-09-21 | 2006-08-01 | Glaxo Group Ltd | Chemical compounds |
| US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| DE102006060597A1 (de) * | 2006-12-21 | 2008-06-26 | Merck Patent Gmbh | Verfahren zur Herstellung von Benzofuran-2-carboxamiden |
| PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
| AU2009225025A1 (en) * | 2008-03-14 | 2009-09-17 | Merck Patent Gmbh | Azaindole compounds for treatment of central nervous system disorders |
| EP2110374A1 (en) * | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
| WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
| EP2338873A1 (en) | 2009-12-22 | 2011-06-29 | Gmeiner, Peter | New aminotetraline derivatives |
| KR101361145B1 (ko) * | 2011-03-10 | 2014-02-12 | 한국화학연구원 | 신규한 벤조퓨란-2-카르복사미드 유도체 및 그의 ｍｃｈ 수용체-1 관련 질환에 대한 치료학적 용도 |
| CN103570698B (zh) * | 2012-08-01 | 2016-08-03 | 江苏恩华药业股份有限公司 | 用于制备维拉佐酮的化合物及其中间体和应用 |
| CN104337812B (zh) | 2013-07-29 | 2018-09-14 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其使用方法和用途 |
| WO2016192657A1 (en) | 2015-06-03 | 2016-12-08 | Sunshine Lake Pharma Co., Ltd. | Substituted piperazine compounds and methods of use and use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4333254A1 (de) | 1993-09-30 | 1995-04-06 | Merck Patent Gmbh | Piperidine und Piperazine |
| DE19730989A1 (de) * | 1997-07-18 | 1999-01-21 | Merck Patent Gmbh | Piperazin-Derivate |
| TW518218B (en) * | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
-
2001
- 2001-03-14 DE DE10112151A patent/DE10112151A1/de not_active Withdrawn
-
2002
- 2002-02-27 PL PL02362844A patent/PL362844A1/xx unknown
- 2002-02-27 KR KR10-2003-7011886A patent/KR20030080083A/ko not_active Withdrawn
- 2002-02-27 US US10/471,584 patent/US7244846B2/en not_active Expired - Fee Related
- 2002-02-27 CN CNB028058135A patent/CN1244578C/zh not_active Expired - Fee Related
- 2002-02-27 JP JP2002581421A patent/JP4485743B2/ja not_active Expired - Fee Related
- 2002-02-27 IL IL15788902A patent/IL157889A0/xx unknown
- 2002-02-27 CZ CZ20032712A patent/CZ20032712A3/cs unknown
- 2002-02-27 WO PCT/EP2002/002093 patent/WO2002083666A1/en not_active Ceased
- 2002-02-27 SK SK1249-2003A patent/SK12492003A3/sk not_active Application Discontinuation
- 2002-02-27 EP EP02729940A patent/EP1368346A1/en not_active Withdrawn
- 2002-02-27 EE EEP200300447A patent/EE200300447A/xx unknown
- 2002-02-27 CA CA2440726A patent/CA2440726C/en not_active Expired - Fee Related
- 2002-02-27 RU RU2003129057/04A patent/RU2003129057A/ru not_active Application Discontinuation
- 2002-02-27 HU HU0303449A patent/HUP0303449A3/hu unknown
- 2002-02-27 BR BR0208040-0A patent/BR0208040A/pt not_active IP Right Cessation
- 2002-02-27 MX MXPA03008140A patent/MXPA03008140A/es unknown
- 2002-03-13 AR ARP020100898A patent/AR035782A1/es not_active Application Discontinuation
-
2003
- 2003-10-09 EC EC2003004798A patent/ECSP034798A/es unknown
- 2003-10-13 ZA ZA200307966A patent/ZA200307966B/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2397981C2 (ru) * | 2005-04-26 | 2010-08-27 | Мерк Патент Гмбх | Способ получения 5-(4-[4-(5-циано-3-индолил)бутил]-1-пиперазинил)бензофуран-2-карбоксамида |
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20032712A3 (cs) | 2004-01-14 |
| HUP0303449A3 (en) | 2005-02-28 |
| WO2002083666A1 (en) | 2002-10-24 |
| US7244846B2 (en) | 2007-07-17 |
| SK12492003A3 (sk) | 2004-03-02 |
| EP1368346A1 (en) | 2003-12-10 |
| PL362844A1 (en) | 2004-11-02 |
| ZA200307966B (en) | 2005-01-13 |
| MXPA03008140A (es) | 2003-12-12 |
| US20050075269A1 (en) | 2005-04-07 |
| EE200300447A (et) | 2003-12-15 |
| IL157889A0 (en) | 2004-03-28 |
| CN1494543A (zh) | 2004-05-05 |
| DE10112151A1 (de) | 2002-09-19 |
| KR20030080083A (ko) | 2003-10-10 |
| CA2440726C (en) | 2011-05-17 |
| JP2004527536A (ja) | 2004-09-09 |
| BR0208040A (pt) | 2004-02-25 |
| CA2440726A1 (en) | 2002-10-24 |
| CN1244578C (zh) | 2006-03-08 |
| JP4485743B2 (ja) | 2010-06-23 |
| HUP0303449A2 (hu) | 2004-01-28 |
| ECSP034798A (es) | 2003-12-01 |
| AR035782A1 (es) | 2004-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003129057A (ru) | Замещенные производные бензофуран-2-карбоксамидов | |
| JP5301501B2 (ja) | ヒスタミンｈ３−受容体リガンドとしての非イミダゾールアルキルアミンと、その治療への応用 | |
| JP2001523712A (ja) | Ｐｄｅ−ｉｖのベンゼンスルホンアミド阻害剤およびそれらの治療的使用 | |
| RU2003134544A (ru) | Амиды антраниловой кислоты, способы их получения, их применение в качестве антиаритмических средств, а также содержащие их фармацевтические композиции | |
| RU2005111969A (ru) | Производные пирролидона в качестве ингибиторов моноаминоксидазы в (мао-в) | |
| JP2005509632A (ja) | プロスタグランジンｅｐ２及び／又はｅｐ４受容体のリガンドとしてのポリアゾリジノン化合物 | |
| KR20030029889A (ko) | 선택적 세로토닌 재흡수 억제제인 페녹시벤질아민 유도체 | |
| RU97119427A (ru) | Сочетание ингибитора усвоения 5-нт с селективным 5-нтia антагонистом | |
| KR101308527B1 (ko) | 비-이미다졸 알킬아민 히스타민 ｈ3-수용체 리간드를이용한 파킨슨씨병, 폐쇄수면무호흡증, 루이체치매, 혈관성치매의 치료 | |
| RU2005100755A (ru) | Фторбензамиды | |
| EP0941991B1 (en) | 2,4-Bis (4-amidino)phenyl furans as anti-pneumocystis carinii agents | |
| JP4966017B2 (ja) | １−シクロプロピルメチル−４−［２−（３，３，５，５−テトラメチルシクロヘキシル）フェニル］ピペラジンの塩および結晶 | |
| RU2007116037A (ru) | Новая кристаллическая форма (3-циано-1н-индол-7-ил)-[4-(4-фторфенэтил)пиперазин-1-ил]метанона, гидрохлорида | |
| CN1993338B (zh) | 二芳基甲基哌嗪衍生物及其制备方法和用途 | |
| RU2220956C2 (ru) | Производные пиперидина, способы их получения, фармацевтическая композиция на их основе и промежуточные вещества | |
| MX2007012070A (es) | Tratamiento de la epilepsia con ligandos del receptor h3 de histamina, tipo alquilaminas no imidazol. | |
| RU2006105711A (ru) | Производные 2, 4-(гидроксиметилфениламино)пиперидин-1-ил-n-(9h-карбазол-3-ил) ацетамина и родственные им соединения в качестве лигандов нейропептида y 5 (npy5), предназначенные для лечения ожирения | |
| HU195644B (en) | Process for producing new phenyl-acetonitril derivatives and pharmaceutical compositions containing them as active components | |
| JP2007516204A (ja) | 選択的セロトニン再取り込み阻害薬および５−ｈｔ２ａ受容体拮抗薬を含有する組成物 | |
| JPH0427984B2 (enExample) | ||
| RU2003124077A (ru) | Пиперазинилкарбонилхинолины и -изохинолины | |
| CN1633413A (zh) | 20－羟基二十碳四烯酸生成抑制剂 | |
| JP2005503330A5 (enExample) | ||
| JP2005298340A (ja) | 疼痛治療薬 | |
| TWI314929B (en) | Novel benzamide derivatives,preparation process thereof and pharmaceutical composition containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20061003 |